Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics

Therapeutic antibodies are the fastest growing class of drugs in the treatment of cancer, and autoimmune and inflammatory diseases that require the concomitant development of assays to monitor therapeutic antibody levels. Here, we demonstrate that the use of Affimer nonantibody binding proteins prov...

Full description

Bibliographic Details

Published in:	BioTechniques
Main Authors:	Hope Adamson, Amanda Nicholl, Christian Tiede, Anna A Tang, Alex Davidson, Helen Curd, Alex Wignall, Robert Ford, James Nuttall, Michael J McPherson, Matt Johnson, Darren C Tomlinson
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-12-01
Subjects:	Affimer reagents anti-idiotypic biotherapeutics diagnostics pharmacokinetics
Online Access:	https://www.future-science.com/doi/10.2144/btn-2019-0089